4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes

Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773

Inclusion Criteria:

• Male and postmenopausal or hysterectomised female patients with type 2 diabetes
• Age >18 and < 70 years
• BMI >18.5 and <40 kg/m2

Exclusion Criteria:

• Antidiabetic treatment with insulin or glitazones or with more than one oral hypoglycaemic agent;
• Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) or a blood glucose level above 400 mg/dl (22.2 mmol/L) postprandially;
• HbA1c > 8.5 %